040-66808040
History
Established in 1991 with the main objective of establishing commercially viable biotech processes for application in medicine, agriculture and industry, Krebshas been a pioneer in fermentation technology in India. Key dates for this relatively young company are:

2015
  • Entered into a strategic alliance with Ipca Labs
2011
  • Unit 1, Nellore is re-inspected by the USFDA and approved
2007
  • Unit 2, Vizag is inspected by EDQM and AFFSAPS (French Health Authority) and approved
2005
  • US Government bans over the counter sales of Anti asthmatics; Ephedrine and Pseudoephedrine resulting in greater product diversification
2003
  • Unit 1, Nellore is inspected by the USFDA and approved
  • Commissions 2.5MW cogeneration power plant at Unit 2 in Vizag
1999
  • Commissions KBIL’s Unit 2 plant in Vizag and starts commercial production of Anti Cholesterols: Lovastatin and Simvastatin
1994
  • Commissions KBIL’s Unit 1 plant in Nellore and starts commercial production of Anti asthmatics; Ephedrine and Pseudoephedrine
1992
  • Makes initial public offering and lists on major stock exchanges HSE and BSE
1991
  • Incorporated as a Public Limited Company by Founder and Chairman and Managing Director, Dr R T Ravi
© Krebs Biochemicals and Industries Limited, 2016. All Rights Reserved